Pharmaceutical

ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Dec 31, 2024 - 06:00
ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

CT-7439 by Carrick Therapeutics for Breast Cancer: Likelihood of Approval

Next Article

ITM-91 by ITM Isotope Technologies Munich for Pancreatic Ductal Adenocarcinoma: ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Sun Pharma’s JAK inhibitor for alopecia

FDA approves Sun Pharma’s JAK inhibitor for alopecia

Jul 28, 2024

STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more

STAT+: Pharmalittle: We’re reading about a Lilly obesit...

Mar 8, 2024

Lumicell co-founder wins Nobel Prize in Chemistry

Lumicell co-founder wins Nobel Prize in Chemistry

Oct 5, 2023